The Effect of 5-Alpha Reductase on Testosterone in Men

Status unconfirmed · Phase 3

Conditions studied: Sex Disorders

In brief

The enzyme 5-alpha reductase is present in small amounts in muscle and converts testosterone to dihydrotestosterone (DHT). Testosterone affects lean body tissue, muscle size, muscle strength, and sexual function in men. This study will evaluate how 5-alpha reductase influences the effects of testosterone in young healthy men.

Key facts

Study ID

NCT00070733

Run by

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

People needed

184

Starts

2003-08-01

Expected to finish

2005-06-01

Last updated by the study team

2005-11-07

Who can join

Age: 21 and older, up to 40. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• General good health and capable of undergoing strength testing
• Normal testosterone (300-1100 ng/dL), LH, and FSH levels

You may not qualify if…

• Currently participating in competitive sports
• Mental state that would preclude complete understanding of the protocol and compliance
• Disorder known to cause or be associated with hypogonadism (e.g., pituitary tumors, hyperprolactinemia, HIV infection, or Klinefelter's Syndrome)
• More than 20% over ideal body weight
• Disabilities that would prevent participation in strength testing (e.g., amputation of limbs, blindness, severe arthritis, angina, or neurologic disorders such as Parkinson's disease, stroke, or myopathy)
• Uncontrolled hypertension, diabetes, congestive heart failure, or chronic obstructive lung disease
• Alcohol or drug dependence in the 6 months prior to study entry
• Disorders that might be exacerbated by androgen treatment (e.g., benign prostatic hyperplasia or prostate cancer, erythrocytosis [hematocrit > 51% at baseline], or sleep apnea assessed by Berlin's questionnaire)
• Serum PSA levels > 4 microg/L
• AST, ALT, or alkaline phosphatase elevation greater than three times the upper limit of normal
• Creatinine greater than 2 mg/dL
• Medications that might affect muscle or bone metabolism (e.g., glucocorticoid, rhGH, androgenic steroids, oral androgen precursors such as androstenedione or DHEA) or androgen metabolism, action, or clearance (e.g., dilantin, phenobarbitol, aldactone, flutamide, finasteride)

Where it is running

• Charles R. Drew University — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.